Abstract: The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone.

Abstract: The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza vims infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone.

Abstract: The present invention relates to MEK inhibitors for use in a method for the treatment of a coronavirus infection and/or the treatment or prevention of COVID-19 cytokine storm. Also provided are compositions comprising such inhibitors for use in the treatment of a corona virus infection, such as COVID-19.

Abstract: The present invention relates to a ROCK inhibitor for use in the treatment or prevention of pulmonary edema associated with a virus infection. The present invention further concerns a use of an in vitro test system or the determination of inhibitors effectiveness in preventing or reducing apical sodium-potassium-ATPase (NKA) localisation in lung epithelial cells. Also provided is a method for detecting molecules effective in the prophylaxis and/or treatment of a pulmonary edema. Finally, the invention relates to a test system.

Abstract: The present invention relates to MEK inhibitor, p38 inhibitor and/or NF?B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.

Abstract: The present invention relates to MEK inhibitor, p38 inhibitor and/or NF?B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.

Abstract: The present invention relates to MEK inhibitors that are capable of displaying one or more beneficial therapeutic effects. The MEK inhibitors can be used in the prevention and/or treatment of viral infection. MEK inhibitors in combination with neuraminidase inhibitor compounds are capable of displaying one or more beneficial therapeutic effects in the treatment of viral diseases.